Common musculoskeletal tumors of childhood and adolescence

Mayo Clinic Proceedings

Volumn 87, Issue 5, 2012, Pages 475-487

  Arndt, Carola A S ^a   Rose, Peter S ^a   Folpe, Andrew L ^a   Laack, Nadia N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MURAMYL TRIPEPTIDE; NAVELBINE; SOMATOMEDIN B; SOMATOMEDIN C; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EWING SARCOMA; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LUNG METASTASIS; MOLECULAR PATHOLOGY; OSTEOSARCOMA; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; RHABDOMYOSARCOMA; THERAPY EFFECT; TUMOR BIOPSY;

EID: 84860669845     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.01.015     Document Type: Conference Paper

References (121)

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531-1543.
2. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance, Epidemiology, and End Results data. J Pediatr Hematol Oncol. 2008;30(6):425-430.
3. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer. 2009;115(18):4218-4226.
4. Mohseny AB, Szuhai K, Romeo S, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009;219(3):294-305.
5. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:467-478.
6. Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch. 2010;456(2):201-217.
7. Folpe AL, Inwards CY. Bone and Soft Tissue Pathology. Philadelphia, PA: Saunders/Elsevier; 2010.
8. Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. Cancer. 2011;117(8):1731-1735.
9. Kurt A-M, Unni KK, McLeod RA, Pritchard DJ. Low-grade intraosseous osteosarcoma. Cancer. 1990;65(6):1418-1428. (Pubitemid 20097173)
10. Han I, Oh JH, Na YG, Moon KC, Kim KS. Clinical outcome of parosteal osteosarcoma. J Surg Oncol. 2008;97(2):146-149. (Pubitemid 351169044)
11. Okada K, Frassica FJ, Sim FH, Beabout JW, Bond JR, Unni KK. Parosteal osteosarcoma: a clinicopathological study. J Bone Joint Surg Am. 1994;76(3):366-378.
12. Raymond AK. Surface osteosarcoma. Clin Orthop Relat Res. 1991;270:140-148.
13. Sheth DS, Yasko AW, Raymond AK, et al. Conventional and dedifferentiated parosteal osteosarcoma: diagnosis, treatment, and outcome. Cancer. 1996;78(10):2136-2145. (Pubitemid 26367606)
14. Rose PS, Dickey ID, Wenger DE, Unni KK, Sim FH. Periosteal osteosarcoma: long-term outcome and risk of late recurrence. Clin Orthop Relat Res. 2006;453:314-317. (Pubitemid 44901000)
15. Weiss SW, Goldblum JR. Enzinger and Weiss' Soft Tissue Tumors. 5th ed. Philadelphia, PA: Mosby Elsevier;2008.
16. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29(8):1025-1033. (Pubitemid 41045546)
17. Khoury JD. Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics. Expert Rev Mol Diagn. 2008;8(1):97-105.
18. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E. W. I. N. G. 99 trial. J Clin Oncol. 2010;28(12):1982-1988.
19. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010;28(12):1989-1994.
20. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol. 2001;14(5):506-514. (Pubitemid 32448750)
21. Parham DM. Correspondence re: Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies [Mod Pathol. 2001;14:506-514]. (Pubitemid 32448750)
22. Mod Pathol. 2001;14(10):1068.
23. Croes R, Debiec-Rychter M, Cokelaere K, De Vos R, Hagemeijer A, Sciot R. Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma. Virchows Arch. 2005;446(1):64-67. (Pubitemid 40179159)
24. Dias P, Chen B, Dilday B, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol. 2000;156(2):399-408. (Pubitemid 30643794)
25. Bahrami A, Gown AM, Baird GS, Hicks MJ, Folpe AL. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. Mod Pathol. 2008;21(7):795-806. (Pubitemid 351896668)
26. Sumegi J, Streblow R, Frayer RW, et al. Recurrent t (2;2) and t (2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2010;49(3):224-236.
27. Gallego Melcón S, Sánchez de Toledo Codina J. Molecular biology of rhabdomyosarcoma. Clin Transl Oncol. 2007;9(7):415-419.
28. Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the Children's Oncology Group. J Clin Oncol. 2010;28(7):1240-1246.
29. Mankin HJ, Mankin CJ, Simon MA. The hazards of biopsy, revisited: for the members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am. 1996;78(5):656-663.
30. Völker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25(34):5435-5441. (Pubitemid 350232220)
31. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23(34):8828-8834. (Pubitemid 46211529)
32. Hawkins DS, Conrad EU III, Butrynski JE, Schuetze SM, Eary JF. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009;115(15):3519-3525.
33. Bielack S, Jürgens H, Jundt G, et al. Osteosarcoma: the COSS experience. Cancer Treat Res. 2009;152:289-308.
34. Meyers PA, Schwartz CL, Krailo MD, et al; Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol. 2008;26(4):633-638. (Pubitemid 351264359)
35. Bacci G, Fabbri N, Balladelli A, Forni C, Palmerini E, Picci P. Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients. J Bone Joint Surg Br. 2006;88(8):1071-1075.
36. Kager L, Zoubek A, Pötschger U, et al; Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21(10):2011-2018. (Pubitemid 46606391)
37. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20(3):776-790. (Pubitemid 34111386)
38. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: an updated report. J Clin Oncol. 2000;18(24):4016-4027. (Pubitemid 32038393)
39. Euramos I Trial. The European and American Osteosarcoma Study Group Web site. http://www.ctu.mrc.ac.uk/euramos/euramos-i-trial.asp. Accessed April 4, 2012.
40. National Cancer Institute. Phase II study of chemotherapy with or without trastuzumab (Herceptin®) in patients with metastatic osteosarcoma. National Cancer Institute Web site. http://www.cancer.gov/clinicaltrials/search/view? cdrid-68882&version-HealthProfessional&protocolsearchid-9547220. Accessed April 9, 2012.
41. Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2011;117(8):1736-1744.
42. National Cancer Institute. Pilot study of zoledronic acid in combination with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma. National Cancer Institute Web site. http://www.cancer.gov/ clinicaltrials/search/view? cdrid-612613&version- HealthProfessional&protocolsearchid-9547220. Accessed April 9, 2012.
43. Ayerza MA, Farfalli GL, Aponte-Tinao L, Muscolo DL. Does increased rate of limb-sparing surgery affect survival in osteosarcoma? Clin Orthop Relat Res. 2010;468(11):2854-2859.
44. Neel MD, Wilkins RM, Rao BN, Kelly CM. Early multicenter experience with a noninvasive expandable prosthesis. Clin Orthop Relat Res. 2003;415:72-81. (Pubitemid 37336520)
45. Musculo DL, Ayerza MA, Aponte-Tinao L, Farfalli GL. Allograft reconstruction after sarcoma excision in children younger than 10 years old. Clin Orthop Relat Res. 2008;466(8):1856-1862.
46. Abed YY, Beltrami G, Campanacci DA, Innocenti M, Scoccianti G, Capanna R. Biological reconstruction after resection of bone tumours around the knee: long-term follow-up. J Bone Joint Surg Br. 2009;91(10):1366-1372.
47. Farfalli GL, Boland PJ, Morris CD, Athanasian EA, Healey JH. Early equivalence of uncemented press-fit and Compress femoral fixation. Clin Orthop Relat Res. 2009;467(11):2792-2799.
48. Cañadell J, Forriol F, Cara JA. Removal of metaphyseal bone tumours with preservation of the epiphysis: physeal distraction before excision. J Bone Joint Surg Br. 1994;76(1):127-132. (Pubitemid 24029273)
49. Teplyakov V, Solovyev J, Aliev M. Transosseous osteosynthesis by Ilizarov in the treatment of patients with primary malignant tumours of long bones. In: Proceedings of the 17th Annual Meeting of the European Musculoskeletal Oncology Society. Oslo, Norway; June 9-11, 2004.
50. Rödl RW, Pohlmann U, Gosheger G, Lindner NJ, Winkelmann W. Rotationplasty-quality of life after 10 years in 22 patients. Acta Orthop Scand. 2002;73(1):85-88.
51. Fuchs B, Kotajarvi BR, Kaufman KR, Sim FH. Functional outcome of patients with rotationplasty about the knee. Clin Orthop Relat Res. 2003;415:52-58. (Pubitemid 37329039)
52. Highsmith MJ, Kahle JT, Bongiorni DR, Sutton BS, Groer S, Kaufman KR. Safety, energy efficiency, and cost efficacy of the C-Leg for transfemoral amputees: a review of the literature [published correction appears in Prosthet Orthot Int. 2011;35(1):113].
53. Prosthet Orthot Int. 2010;34(4):362-377.
54. Fuchs B, Yaszemski MJ, Sim FH. Combined posterior pelvis and lumbar spine resection for sarcoma. Clin Orthop Relat Res. 2002;397:12-18. (Pubitemid 34442010)
55. Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 2011;117(19):4522- 4530.
56. Blattmann C, Oertel S, Schulz-Ertner D, et al. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer. 2010;10:96.
57. Jingu K, Tsujii H, Mizoe JE, et al; Organizing Committee for the Working Group for Head-and-Neck Cancer. Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;82(5):2125-2131.
58. Hillegonds DJ, Franklin S, Shelton DK, Vijayakumar S, Vijayakumar V. The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc. 2007;99(7):785-794. (Pubitemid 47076147)
59. Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S. The role of radiotherapy in oseosarcoma. Cancer Treat Res. 2009;152:147-164.
60. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694-701. (Pubitemid 36237038)
61. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009;27(15):2536-2541.
62. Womer RB, West DC, Krailo MD, Dickman PS, Pawel B; Children's Oncology Group AEWS0031 Committee. Randomized comparison of every-two-week v. every-threeweek chemotherapy in Ewing sarcoma family tumors (ESFT) [abstract]. J Clin Oncol. 2008;26(15, suppl):10504.
63. National Cancer Institute. Phase III randomized study of adding vincristine sulfate, topotecan hydrochloride, and cyclophosphamide to standard chemotherapy in patients with non-metastatic extracranial Ewing sarcoma. National Cancer Institute Web site. http://www.cancer.gov/clinicaltrials/search/ view?cdrid-687639& version-HealthProfessional&protocolsearchid-9547232.
64. National Cancer Institute. Phase III randomized study of standard induction chemotherapy comprising vincristine, dactinomycin, ifosfamide, and etoposide followed by consolidation chemotherapy comprising vincristine, dactinomycin, and ifosfamide versus high-dose busulfan and melphalan followed by autologous peripheral blood stem cell support with or without radiotherapy and/or surgery in patients with tumor of the Ewing's family. National Cancer Institute Web site. http://www.cancer.gov/clinicaltrials/search/view?cdrid- 68608&version-HealthProfessional&protocolsearchid-9547232. Access April 9, 2012.
65. Rosenthal J, Pawlowska AB. High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors. Expert Rev Anticancer Ther. 2011;11(2):251-262.
66. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010;11(2):184-192.
67. Fuchs B, Valenzuela RG, Inwards C, Sim FH, Rock MG. Complications in long-term survivors of Ewing sarcoma. Cancer. 2003;98(12):2687-2692. (Pubitemid 37509534)
68. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009;27(15):2536-2541.
69. Donati D, Yin J, Di Bella C, et al. Local and distant control in non-metastatic pelvic Ewing's sarcoma patients. J Surg Oncol. 2007;96(1):19-25. (Pubitemid 47015444)
70. Yock TI, Krailo M, Fryer CJ, et al; Children's Oncology Group. Local control in pelvic Ewing sarcoma: analysis from INT-0091-a report from the Children's Oncology Group. J Clin Oncol. 2006;24(24):3838-3843. (Pubitemid 46655603)
71. Yang RS, Eckardt JJ, Eilber FR, et al. Surgical indications for Ewing's sarcoma of the pelvis. Cancer. 1995;76(8):1388-1397.
72. Frassica FJ, Frassica DA, Pritchard DJ, Schomberg PJ, Wold LE, Sim FH. Ewing sarcoma of the pelvis: clinicopathologic features and treatment. J Bone Joint Surg Am. 1993;75(10):1457-1465. (Pubitemid 23358233)
73. Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer. 2004;42(5):465-470. (Pubitemid 38524480)
74. Liu AK, Stinauer M, Albano E, Greffe B, Tello T, Maloney K. Local control of metastatic sites with radiation therapy in metastatic Ewing sarcoma and rhabdomyosarcoma. Pediatr Blood Cancer. 2011;57(1):169-171.
75. Haeusler J, Ranft A, Boelling T, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010;116(2):443-450.
76. Ferrari A, Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev Anticancer Ther. 2005;5(2):283-294. (Pubitemid 40553093)
77. Sultan I, Ferrari A. Selecting multimodal therapy for rhabdomyosarcoma. Expert Rev Anticancer Ther. 2010;10(8):1285-1301.
78. Crist WM, Anderson JR, Meza JL, et al; Intergroup Rhabdomyosarcoma Study Group (IRSG). Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091-3102. (Pubitemid 32567502)
79. Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005;23(12):2618-2628. (Pubitemid 46179450)
80. Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011;29(10):1312-1318.
81. Walterhouse D, Pappo AS, Meza JL, et al. Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): a report from the Children's Oncology Group (COG) [abstract]. J Clin Oncol. 2011;29(15, suppl):9516.
82. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol. 2009;27(31):5182-5188.
83. National Cancer Institute. Phase III randomized study of vincristine, dactinomycin, and cyclophosphamide (VAC) versus VAC alternating with vincristine and irinotecan hydrochloride in combination with radiotherapy in patients with newly diagnosed, intermediate-risk rhabdomyosarcoma. National Cancer Institute Web site. http://www.cancer.gov/clinicaltrials/search/view?cdrid- 487560&protocolsearchid-9398356&version-healthprofessional. Accessed April 9, 2012.
84. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26(14):2384-2389.
85. Carli M, Colombatti R, Oberlin O, et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors [published correction appears in J Clin Oncol. 2005;23(1):248].
86. J Clin Oncol. 2004;22(23):4787-4794.
87. Bisogno G, Ferrari A, Prete A, et al. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur J Cancer. 2009;45(17):3035-3041.
88. Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 2001;23(5):272-276. (Pubitemid 32662033)
89. Stevens MC. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol. 2005;6(2):77-84. (Pubitemid 40197701)
90. Donaldson SS, Anderson JR. Rhabdomyosarcoma: many similarities, a few philosophical differences [editorial]. J Clin Oncol. 2005;23(12):2586-2587. (Pubitemid 46179444)
91. Ritchey M, Ferrer F, Shearer P, Spunt SL. Late effects on the urinary bladder in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52(4):439-446.
92. Nagarajan R, Kamruzzaman A, Ness KK, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Cancer. 2011;117(3):625-634.
93. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(16):1272-1283.
94. Aksnes LH, Bauer HC, Dahl AA, et al. Health status at long-term follow-up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: a Scandinavian sarcoma group study. Pediatr Blood Cancer. 2009;53(1):84-89.
95. Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2005;44(7):643-653. (Pubitemid 40629215)
96. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083-1095.
97. Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C. Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer. 2008;44(7):983-991.
98. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the Childhood Cancer Survivor Study. Radiat Res. 2010;174(6):840-850.
99. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Children's Oncology Group Web site. http://www.survivorshipguidelines.org/. Accessed April 9, 2012.
100. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005;65(9):3868-3876. (Pubitemid 40616368)
101. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An antiinsulinlike growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003;63(16):5073-5083. (Pubitemid 37022647)
102. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2008;50(6):1190-1197. (Pubitemid 351555543)
103. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011;29(34):4534-4540.
104. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol. 2010;28(33):4985-4995.
105. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011;29(34):4541-4547.
106. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30(1):78-84.
107. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400. (Pubitemid 38618122)
108. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000;60(22):6253-6258.
109. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2008;50(4):799-805. (Pubitemid 351354788)
110. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptortargeting antibody, CP-751, 871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009;69(19):7662-7671.
111. Tillander J, Hagberg K, Hagberg L, Brånemark R. Osseointegrated titanium implants for limb prostheses attachments: infectious complications. Clin Orthop Relat Res. 2010;468(10):2781-2788.
112. Hagberg K, Brånemark R. One hundred patients treated with osseointegrated transfemoral amputation prostheses-rehabilitation perspective. J Rehabil Res Dev. 2009;46(3):331-344.
113. Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys. 2012;82(2):635-642.
114. Rombi B, De Laney TF, MacDonald SM, et al. Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys. 2012;82(3):1142-1148.
115. Merchant TE. Proton beam therapy in pediatric oncology. Cancer J. 2009;15(4):298-305.
116. Patel S, De Laney TF. Advanced-technology radiation therapy for bone sarcomas. Cancer Control. 2008;15(1):21-37. (Pubitemid 351481989)
117. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys. 2002;54(3):824-829.
118. De Laney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009;74(3):732-739.
119. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947-952. (Pubitemid 350002860)
120. Levine AM, Coleman C, Horasek S. Stereotactic radiosurgery for the treatment of primary sarcomas and sarcoma metastases of the spine. Neurosurgery. 2009;64(2, suppl):A54-A59.
121. Bilsky MH, Yenice K, Lovelock M, Yamada J. Stereotactic intensity-modulation radiation therapy for vertebral body and paraspinal tumors. Neurosurg Focus. 2001;11(6):e7.